Affordable Access

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.

Authors
  • Huang, Juan
  • Garmise, Robert J
  • Crowder, Timothy M
  • Mar, Kevin
  • Hwang, C Robin
  • Hickey, Anthony J
  • Mikszta, John A
  • Sullivan, Vincent J
Type
Published Article
Journal
Vaccine
Publisher
Elsevier
Publication Date
Dec 21, 2004
Volume
23
Issue
6
Pages
794–801
Identifiers
PMID: 15542204
Source
Medline
License
Unknown

Abstract

Intranasal (i.n.) vaccination represents an attractive non-invasive alternative to needle-based injection and provides superior protection at mucosal surfaces. However, new formulations are needed to improve efficacy and reduce the refrigerated storage and distribution requirements associated with standard liquid vaccines. Here, we describe a powder formulation of whole inactivated influenza virus and a novel i.n. delivery platform. The powder-formulated vaccine elicited a significant serum antibody response in rats that was at least as strong as that provided by the liquid vaccine administered i.n. or via intramuscular (i.m.) injection. Significant nasal IgA responses were also observed solely after i.n. delivery. This study demonstrates for the first time the generation of potent nasal mucosal and systemic immune responses using an i.n. delivered influenza vaccine powder and suggests an alternative approach to vaccination against influenza and other infectious diseases.

Report this publication

Statistics

Seen <100 times